日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Improved survival, disparate outcomes contemporaneously define the modern worldwide burden of childhood cancers

生存率的提高与治疗结果的差异,共同构成了当今全球儿童癌症负担的现状。

Kudek, Matthew R; Wang, Hao

Nonpharmacologic interventions for managing distress, anxiety, and depression for patients with cancer and their family caregivers: A systematic review and meta-analysis

针对癌症患者及其家庭照护者,非药物干预在缓解痛苦、焦虑和抑郁方面的应用:系统评价和荟萃分析

Schiess, Lisa C; Song, Lixin L; Schädelin, Sabine; Fürst, Thomas; Urech, Corinne; Friese, Christopher R; Katapodi, Maria C

A patient with newly diagnosed breast cancer found to have mosaic TP53 likely pathogenic variant

一名新确诊乳腺癌的患者被发现携带TP53嵌合型可能致病变异。

Mistry, Hetal D; Adams, MacKenzie R; Taneja, Charu; Massingham, Lauren J; Dibble, Elizabeth H; Leonard, Kara L; Hart, Jesse; Lagos, Galina G; Fenton, Mary Anne

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

2025年泌尿系统晚期肿瘤共识会议(AUC3):肾细胞癌和泌尿系统肿瘤治疗的专家共识

McKay, Rana R; Pal, Sumanta; Xie, Wanling; Aggen, David; Albiges, Laurence; Apolo, Andrea; Atkins, Michael B; Bangs, Rick; Beckermann, Kathryn E; Bellmunt, Joaquim; Berg, Stephanie A; Bilen, Mehmet A; Braun, David; Carlo, Maria I; Efstathiou, Jason; Galsky, Matthew; Grivas, Petros; Gupta, Shilpa; Haas, Naomi; Hakimi, A Ari; Hammers, Hans; Heng, Daniel Y C; Hirsch, Michelle; Iyer, Gopakumar; Jonasch, Eric; Koshkin, Vadim S; Kryvenko, Oleksandr; Lewis, Bryan; Li, Roger; Matin, Surena; Maughan, Benjamin; McDermott, David F; McGregor, Bradley; Meeks, Joshua; Milowsky, Matthew; Motzer, Robert; Necchi, Andrea; Petrylak, Dan; Porten, Sima; Powles, Thomas; Rini, Brian; Shuch, Brian; Siefker-Radtke, Arlene; Sonpavde, Guru; Sridhar, S Srikala; Suarez, Cristina; Tang, Chad; Tripathi, Abhishek; Van Der Heijden, Michiel S; Voss, Martin; Xu, Wenxin; Zhang, Tian; Rosenberg, Jonathan; Choueiri, Toni K

Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention

通过补水预防尿路结石:一项依从性干预的随机临床试验

Desai, Alana C; Maalouf, Naim M; Harper, Jonathan D; Sivalingam, Sri; Lieske, John C; Lai, H Henry; Reese, Peter P; Wessells, Hunter; Yang, Hongqiu; Al-Khalidi, Hussein R; Kirkali, Ziya; Tasian, Gregory E; Scales, Charles D Jr

Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer

阿特珠单抗联合FOLFOX方案治疗III期错配修复缺陷型结肠癌

Sinicrope, Frank A; Ou, Fang-Shu; Arnold, Dirk; Peters, Walter R; Behrens, Robert J; Lieu, Christopher H; Matin, Khalid; Cohen, Deirdre J; Potter, Samara L; Nixon, Andrew B; Kottschade, Lisa A; Kathol, Emily; Frankel, Wendy L; Shergill, Ardaman; Hsu, Dennis; Reinacher-Schick, Anke; Mehan, Paul; Gold, Philip J; Khalil, Maged F; Zemla, Tyler; Gatten, Clare; O'Reilly, Eileen M; Meyerhardt, Jeffrey A

The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study

非小细胞肺癌软脑膜转移的演变格局:一项国际性、当代、多中心队列研究

Zheng, M M; Xia, Y; Pan, K; Sun, F; Tan, A C; Dong, X R; Tu, H Y; Tang, L B; Li, Y S; Yin, K; Borgeaud, M; Singhal, S; Zhu, E; Zhang, J; Nilsson, M; Wu, J; Gibbons, D L; Wakelee, H; Neal, J W; Lee, J; Vaporciyan, A A; Ringsurongkawong, W; Tran, H T; Zhang, R Z; Zhang, T; Zhou, Q; Zhong, W Z; Li, W; Zhang, Y C; Riess, J W; Addeo, A; Heymach, J V; Myall, N; Tan, D; Wu, Y L; Le, X

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

CheckMate 9ER 随机 III 期试验中,对纳武利尤单抗联合卡博替尼治疗晚期肾细胞癌的最终分析

Motzer, R J; Escudier, B; Burotto, M; Powles, T; Apolo, A B; Bourlon, M T; Shah, A Y; Porta, C; Suárez, C; Barrios, C H; Richardet, M; Gurney, H; Kessler, E R; Tomita, Y; Bedke, J; Scheffold, C; Askelson, M; Panzica, J; Zhang, J; van Kooten Losio, M; Choueiri, T K

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies

MTAP缺失在癌基因驱动的非小细胞肺癌中很常见,并可能使肿瘤对PRMT5抑制剂和靶向治疗联合治疗敏感。

Aldea, M; Lenahan, S; Locquet, M-A; Liao, L; Gasparro, M; Gokhale, P C; Ghigna, M-R; Ionescu, D N; Odintsov, I; Ngo, K; Wang, X; Aziz, S; Pecci, F; Garbo, E; Ivanova, E; Nakazawa, S; Kulesza, J; Tsai, J A; Zullo, L; Lee, J; Zielinska, M; Simon, S; Han, D; Marinello, A; Li, G; Rossato de Almeida, G; Huang, J; Paoloni, F; Gariazzo, E; Santo, V; Remon, J; Marks, J A; LoPiccolo, J; Florez, N; Nishino, M; Ricciuti, B; Luo, J; Barbie, D A; Planchard, D; Rotow, J K; Barlesi, F; Graf, R P; Feng, W W; Besse, B; Paweletz, C; Sholl, L; Shaw, A T; Jänne, P A

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.

利拉夫替尼选择性抑制FGFR2的临床耐药机制。

Ellis H, Balasooriya E R, Varkaris A, Hajian B, Wan J, Shekhar M, Gritti I, Vijay V, Albertelli L, Piot S, Lau K, Kehlmann A, Chevalier N, Nugent F W, Zhen Y, Silveira V S, Sellers W R, Corcoran R B, Juric D, Bardeesy N